Cibc World Market Inc. Acquires New Stake in Eupraxia Pharmaceuticals Inc. $EPRX

Cibc World Market Inc. acquired a new stake in shares of Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) in the second quarter, Holdings Channel reports. The firm acquired 234,673 shares of the company’s stock, valued at approximately $1,539,000.

Several other hedge funds have also added to or reduced their stakes in EPRX. Vivo Capital LLC purchased a new stake in shares of Eupraxia Pharmaceuticals in the third quarter worth $7,965,000. Affinity Asset Advisors LLC raised its position in shares of Eupraxia Pharmaceuticals by 429.7% in the 1st quarter. Affinity Asset Advisors LLC now owns 1,589,005 shares of the company’s stock worth $11,504,000 after purchasing an additional 1,289,005 shares during the last quarter. Seven Fleet Capital Management LP purchased a new position in shares of Eupraxia Pharmaceuticals in the 1st quarter worth about $5,137,000. Redmile Group LLC bought a new position in Eupraxia Pharmaceuticals in the 1st quarter worth about $5,068,000. Finally, Rubric Capital Management LP bought a new position in Eupraxia Pharmaceuticals in the 1st quarter worth about $5,004,000.

Eupraxia Pharmaceuticals Trading Down 0.9%

NASDAQ:EPRX opened at $7.36 on Friday. The company has a market cap of $478.55 million, a PE ratio of -7.22 and a beta of 1.08. The company has a current ratio of 16.00, a quick ratio of 16.00 and a debt-to-equity ratio of 0.02. The company has a 50 day simple moving average of $6.60 and a two-hundred day simple moving average of $7.04. Eupraxia Pharmaceuticals Inc. has a 12 month low of $5.12 and a 12 month high of $9.32.

Eupraxia Pharmaceuticals (NASDAQ:EPRX) last released its quarterly earnings results on Tuesday, August 11th. The company reported ($0.23) earnings per share for the quarter, beating the consensus estimate of ($0.25) by $0.02. Research analysts forecast that Eupraxia Pharmaceuticals Inc. will post -0.87 earnings per share for the current year.

Analyst Upgrades and Downgrades

EPRX has been the topic of several recent analyst reports. Zacks Research raised shares of Eupraxia Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Thursday, May 7th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Eupraxia Pharmaceuticals in a report on Friday, July 17th. Wall Street Zen downgraded shares of Eupraxia Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Saturday, May 16th. Oppenheimer assumed coverage on shares of Eupraxia Pharmaceuticals in a report on Thursday, June 25th. They set an “outperform” rating and a $17.00 price target on the stock. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Eupraxia Pharmaceuticals in a research report on Wednesday, July 15th. Two analysts have rated the stock with a Strong Buy rating, five have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Eupraxia Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average target price of $18.00.

Eupraxia Pharmaceuticals Profile

Eupraxia Pharmaceuticals, Inc (NASDAQ: EPRX) is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for autoimmune and inflammatory diseases. The company’s core strategy centers on selectively expanding regulatory T cells (Tregs)—immune cells responsible for maintaining self-tolerance and limiting pathological inflammation—through its proprietary platform. Its lead therapeutic candidate is currently in Phase 1 clinical development in patients with systemic lupus erythematosus.

Based in Seattle, Washington, Eupraxia Pharmaceuticals conducts research and development activities across North America, collaborating with academic institutions and contract research organizations to advance its pipeline.